Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FZD3 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- Chang Group
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FZD3 small interfering RNA is an RNA interference (RNAi) therapeutic candidate designed to silence the expression of the Frizzled-3 (FZD3) receptor. FZD3 is a member of the Frizzled family of G protein-coupled receptors that serve as receptors for Wnt signaling proteins, specifically within the planar cell polarity (PCP) pathway. In the context of cutaneous melanoma, FZD3 is often highly expressed and is thought to play a redundant role with FZD6 in promoting tumor cell proliferation, migration, and invasion. By specifically targeting and degrading FZD3 mRNA, this siRNA aims to inhibit these oncogenic processes. Research conducted by the Chang group has demonstrated that dual knockdown of FZD3 and FZD6 significantly decreases melanoma cell proliferation compared to single knockdowns, suggesting a potential therapeutic strategy for treatment-resistant melanoma.
- Other names
- FZD3 siRNAFZD-3 siRNAFZD 3 siRNA
02
Targets
FZD (Frizzled receptor family)
Beyond the preview
Go deeper on FZD3 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FZD3 small interfering RNA.